Advertisement

Strahlentherapie und Onkologie

, Volume 192, Issue 1, pp 47–54 | Cite as

Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma

  • Margret Rave-Fränk
  • Narges Tehrany
  • Julia Kitz
  • Martin Leu
  • Hanne Elisabeth Weber
  • Peter Burfeind
  • Henning Schliephake
  • Martin Canis
  • Tim Beissbarth
  • Holger Michael Reichardt
  • Hendrik Andreas Wolff
Original Article

Abstract

Objective

The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy.

Methods

Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16INK4A status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression.

Results

CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16INK4A positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034).

Conclusion

A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.

Keywords

Head and neck cancer Squamous cell cancer Chemokines Radio(chemo)therapy Prognosis 

Prognostischer Stellenwert von CXCL12 und CXCR4 bei inoperablen Kopf-Hals-Tumoren

Zusammenfassung

Hintergrund

Das Chemokin CXCL12 und sein Rezeptor CXCR4 beeinflussen Tumorwachstum, Auftreten von Rezidiven und Metastasierung. Es wurde die Hypothese geprüft, dass ein Zusammenhang der CXCL12- und CXCR4-Expression mit der Prognose von Patienten bestehe, die wegen eines inoperablen Kopf-Hals-Tumors eine primäre Radio- oder Radiochemotherapie erhielten. Dabei wurde auch der HPV-Status der Patienten berücksichtigt.

Methodik

Formalinfixierte Proben aus unbehandelten Tumoren von 233 Patienten mit bekanntem HPV/p16INK4A-Status wurden ausgewertet. Die CXCL12- und CXCR4-Expression wurde mit klinischen Parametern und Überlebensdaten mittels uni- und multivariater Cox Regression analysiert.

Ergebnisse

CXCL12 wurde von 43,3 %, CXCR4 von 66,1 % der Tumoren exprimiert, und beide Marker korrelierten mit einer HPV/p16INK4A-Expression. Eine hohe CXCL12-Expression war mit einem verbesserten Gesamtüberleben (p = 0,036), eine hohe CXCR4-Expression mit einem reduzierten fernmetastasenfreien Überleben (p = 0,034) assoziiert.

Schlussfolgerung

Eine hohe CXCR4-Expression erscheint auch für Patienten mit inoperablen Kopf-Hals-Tumoren als negativer prognostischer Faktor, weil es Metastasierungsprozesse fördert. Eine gezielte Unterdrückung der CXCL12-/CXCR4-Signalwege kann eine Möglichkeit zur Reduktion der Metastasierung sein.

Schlüsselwörter

Kopf-Hals-Plattenepithelkarzinom Plattenepithelkarzinome Chemokin Radio(chemo)therapie Prognose 

Notes

Compliance with ethical guidelines

Conflict of interest

M. Rave-Fränk, N. Tehrany, J. Kitz, M. Leu, H.E. Weber, P. Burfeind, H. Schliephake, M. Canis, T. Beissbarth, H.M. Reichardt, and H.A. Wolff state that there are no conflicts of interest.

References

  1. 1.
    Heiduschka G, Grah A, Oberndorfer F et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191:209–216PubMedCrossRefGoogle Scholar
  2. 2.
    Takes RP, Rinaldo A, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol 48:775–779PubMedCrossRefGoogle Scholar
  3. 3.
    Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230PubMedCrossRefGoogle Scholar
  4. 4.
    Albert S, Riveiro ME, Halimi C et al (2013) Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. Head Neck 35:1819–1828PubMedCrossRefGoogle Scholar
  5. 5.
    Katayama A, Ogino T, Bandoh N et al (2005) Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 11:2937–2946PubMedCrossRefGoogle Scholar
  6. 6.
    Uchida D, Onoue T, Tomizuka Y et al (2007) Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 5:685–694PubMedCrossRefGoogle Scholar
  7. 7.
    Salcedo R, Wasserman K, Young HA et al (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125–1135PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ishikawa T, Nakashiro K, Hara S et al (2006) CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 28:61–66PubMedGoogle Scholar
  9. 9.
    Keeley EC, Mehrad B, Strieter RM (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91–111PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Ueda M, Shimada T, Goto Y et al (2010) Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx 37:488–495PubMedCrossRefGoogle Scholar
  11. 11.
    Clatot F, Picquenot JM, Choussy O et al (2011) Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 47:1062–1068PubMedCrossRefGoogle Scholar
  12. 12.
    Tehrany N, Kitz J, Rave-Fränk M et al (2015) High-grade acute organ toxicity and p16 expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma. Strahlenther Onkol 191:566–572PubMedCrossRefGoogle Scholar
  13. 13.
    Wolff HA, Bosch J, Jung K et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRefGoogle Scholar
  14. 14.
    Wolff HA, Daldrup B, Jung K et al (2011) High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. Radiology 258:864–871PubMedCrossRefGoogle Scholar
  15. 15.
    Meng X, Wuyi L, Yuhong X et al (2010) Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation. J Oral Pathol Med 39:63–68PubMedCrossRefGoogle Scholar
  16. 16.
    Li KC, Huang YH, Ho CY et al (2012) The role of IL-8 in the SDF-1alpha/CXCR4-induced angiogenesis of laryngeal and hypopharyngeal squamous cell carcinoma. Oral Oncol 48:507–515PubMedCrossRefGoogle Scholar
  17. 17.
    Uchida D, Onoue T, Kuribayashi N et al (2011) Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 47:452–459PubMedCrossRefGoogle Scholar
  18. 18.
    Ou DL, Chien HF, Chen CL et al (2008) Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 28:1355–1359PubMedGoogle Scholar
  19. 19.
    Taki M, Higashikawa K, Yoneda S et al (2008) Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 19:993–998PubMedGoogle Scholar
  20. 20.
    Ishikawa T, Nakashiro K, Klosek SK et al (2009) Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep 21:707–712PubMedGoogle Scholar
  21. 21.
    Ramsey DM, McAlpine SR (2013) Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett 23:20–25PubMedCrossRefGoogle Scholar
  22. 22.
    McDermott DH, Liu Q, Velez D et al (2014) A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 123:2308–2316PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Cipriani NA, Blair E, Taxy JB (2010) WHIM syndrome and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:105–108PubMedCrossRefGoogle Scholar
  24. 24.
    Clatot F, Gouerant S, Mareschal S et al (2014) The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol 50:200–207PubMedCrossRefGoogle Scholar
  25. 25.
    Rainsbury JW, Ahmed W, Williams HK et al (2013) Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 35:1048–1055PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Margret Rave-Fränk
    • 1
  • Narges Tehrany
    • 1
  • Julia Kitz
    • 2
  • Martin Leu
    • 1
  • Hanne Elisabeth Weber
    • 1
  • Peter Burfeind
    • 3
  • Henning Schliephake
    • 4
  • Martin Canis
    • 5
  • Tim Beissbarth
    • 6
  • Holger Michael Reichardt
    • 7
  • Hendrik Andreas Wolff
    • 1
  1. 1.Department of Radiotherapy and Radiation OncologyUniversity Medical Center GöttingenGöttingenGermany
  2. 2.Department of PathologyUniversity Medical Center GöttingenGöttingenGermany
  3. 3.Department of Human GeneticsUniversity Medical Center GöttingenGöttingenGermany
  4. 4.Department of Oral and Maxillofacial SurgeryUniversity Medical Center GöttingenGöttingenGermany
  5. 5.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Medical Center GöttingenGöttingenGermany
  6. 6.Institute of Medical StatisticsUniversity Medical Center GöttingenGöttingenGermany
  7. 7.Institute for Cellular and Molecular ImmunologyUniversity Medical Center GöttingenGöttingenGermany

Personalised recommendations